Attune Neurosciences
CompanyUnited States
Attune Neurosciences develops one asset, in human trials (ATTN201 in Alzheimer's disease). Mostly device acting on proteostasis; based in the United States.
- 1
- Asset
- Furthest stage
- Human trials
- 0
- Trials
- 1
- Signal
Pipeline
1Focused ultrasound stimulates the thalamic centromedian nucleus to enhance deep-sleep brain waves and glymphatic amyloid clearance.
Human trials, Device, Proteostasis, Alzheimer's disease, mild cognitive impairment
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals1
- Similar companies6